Passer au contenu principal

Subventions financées

Filtrer par:
Effacer les filtres
Filtrer par:
Janice Robertson × Effacer les filtres

5 résultats trouvés

Effects of C9orf72 Deficiency on Inducing Neuronal Hyperexcitability In Vivo

A G4C2 repeat expansion in C9orf72 (chromosome 9 open reading frame 72), a gene of unclear function, is the most frequent genetic cause of Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (C9-ALS/FTD).


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2022

Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS

Amyotrophic lateral sclerosis (ALS) is a terminal disease that paralyzes people because the brain is no longer able to communicate with the muscles that we are typically able to move at will.


TYPE DE SUBVENTION
Subventions de la plate-forme
Domaine de recherche
Neurodégénérescence
Province
Alberta
DATE DE DÉBUT
2021

Pathogenic Mechanism of C9orf72 haploinsufficiency in ALS/FTLD: a road to therapeutic discovery

In this Hudson project, the team led by Dr. Robertson will pursue a comprehensive understanding of the normal functions of C9ORF72 and provide a better determination of whether loss of these functions via mutation may cause or contribute to ALS.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2017

Z-BRAIN: A Zebrafish Drug Screening Platform Targeting Brain Disorders

The traditional target-based drug development strategy (in vitro screening) has had poor success in developing new drugs.


TYPE DE SUBVENTION
Subventions de la plate-forme
Domaine de recherche
Neurotechnologie
Province
Ontario
DATE DE DÉBUT
2015

Characterizing the C9ORF72 protein interactome for identifying novel pathogenic pathways in ALS

In late 2011, a landmark discovery was made which identified that abnormalities (mutation) in a gene called C9ORF72 were responsible for the highest percentage of hereditary ALS and frontotemporal dementia cases.


TYPE DE SUBVENTION
Subventions d'équipe
Domaine de recherche
Neurodégénérescence
Province
Ontario
DATE DE DÉBUT
2015